A Clinical Study on the Impact of Tigecycline on Coagulation Function in Critically Ill Patients with Severe Infections
DOI:
https://doi.org/10.54097/9f7jpf37Keywords:
Tigecycline, Severe Infection, Coagulation Function, Inflammatory CytokinesAbstract
Objective: A Clinical Study on the Effect of Tigecycline on Coagulation Function in Severe Infected Patients. Methods: A total of 90 patients with severe infections, selected from October 2022 to October 2023, were divided into control and observation groups of 45 cases each using a computer-generated random number table. The control group received monotherapy with an antibacterial agent, while the observation group underwent combined therapy with cefoperazone-sulbactam and tigecycline. The clinical efficacy of the two groups was compared. Results: Prior to treatment, there were no statistically significant differences in coagulation indices between the two groups (P > 0.05). Post-treatment, the Fib, APTT, and PT values, as well as clinical efficacy, were higher in the observation group compared to the control group. Conversely, adverse reactions, hs-CRP, PCT, IL-6, and TNF-α values were lower in the observation group, with statistically significant differences (P < 0.05). Conclusion: The observation group experienced fewer adverse reactions, with a statistically significant difference (P < 0.05). Conclusion: Although cefoperazone sulbactam combined with tigecycline has an impact on the coagulation function of patients, its therapeutic effect is superior to other single-drug regimens, and other adverse reactions are relatively mild. Therefore, it is worth considering the combination of tigecycline in the treatment of severe infections, and actively monitoring the coagulation function.
Downloads
References
[1] Chen Xiaowen, Gao Xing. Analysis of the effects of 73 cases of tigecycline on coagulation function in patients with severe infections[J]. China Prescription Drugs,2022,20(10):92-93.
[2] HE Cailing. Clinical retrospective study on the effect of tigecycline on coagulation function in patients with severe infections [D]. Dalian Medical University, 2022.DOI: 10. 26994/ d.cnki.gdlyu.2022.000351.
[3] Liu R, Wang L. Effect of tigecycline on coagulation function of ICU patients with severe infection and analysis of risk factors [J]. Journal of Clinical Rational Drug Use,2021, 14(28): 5-7.DOI:10.15887/j.cnki.13-1389/r.2021.28.002.
[4] Leng B, Xue Y C, Zhang W, et al. A retrospective analysis of the effect of tigecycline on coagulation function[J]. Chemical and Pharmaceutical Bulletin, 2019, 67(3): 258-264.
[5] Hu J, **ao Y, Zheng Y, et al. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients[J]. European journal of clinical pharmacology, 2020, 76: 913-922.
[6] Wang D, Lin C, Gu C, et al. Tigecycline-associated coagulopathy: a single-center retrospective analysis[J]. Pharmacology, 2022, 107(9-10): 524-536.
[7] Li M, He J, Dong G, et al. Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients[J]. Journal of Antimicrobial Chemotherapy, 2024: dkae396.
[8] Sun L H, Bai K H, Wu G Y, et al. Mechanism of abnormal coagulation induced by tigecycline in cancer patients[J]. Frontiers in Pharmacology, 2022, 13: 891952.
[9] Sun H, Meng X, Shao X, et al. Impact of Tigecycline on Coagulation in Severe Infections and Effect of Vitamin K1 Intervention: A Retrospective Single-Center Analysis[J]. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2024, 30: e944778.
[10] Li M, He J, Dong G, et al. Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients[J]. Journal of Antimicrobial Chemotherapy, 2024: dkae396.
[11] Bai X, Wang Z, Li W, et al. Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units[J]. BMC Infectious Diseases, 2023, 23(1): 830.
[12] Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting[J]. International Journal of Clinical Pharmacy, 2020, 42: 1184-1189.
[13] Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database[J]. Thrombosis journal, 2022, 20(1): 12.
[14] Treml B, Rajsic S, Hell T, et al. Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis[J]. Journal of Clinical Medicine, 2021, 10(20): 4702.
[15] Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline‐induced hypofibrinogenaemia[J]. Journal of Clinical Pharmacy and Therapeutics, 2020, 45(6): 1434-1441.
[16] Heng J, Zhang X, Liang F, et al. Tigecycline Induced Fibrinogen Decrease in Critically Ill Patients with Multidrug Resistant Bacterial Infections-an Observational Retrospective Study[J]. 2022.
[17] Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia[J]. Therapeutics and Clinical Risk Management, 2021: 325-332.
[18] Wang D, Wu G, Li X, et al. Clinical Investigation and Biological Mechanism of Tigecycline on Coagulation Disorders in Cancer Patients[J]. Blood, 2020, 136: 25.
[19] Lin C, Tan M, Wang D, et al. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study[J]. Pharmacology, 2023, 108(6): 540-549.
[20] Zhu Y, Zhao F, ** P. Clinical Manifestations and Risk Factors of Tigecycline-Associated Thrombocytopenia[J]. Infection and Drug Resistance, 2023: 6225-6235.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.